Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01266460 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase 2 study, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
NCT01266460 is a Phase 2 study that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 54 participants.
The verdict
NCT01266460, a Phase 2 study, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
Study Summary
This phase II trial studies the side effects and how well vaccine therapy works in treating patients with cervical cancer that does not go to remission despite treatment (persistent) or has come back (recurrent). Vaccines therapy may help the body build an effective immune response to kill tumor cells.
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2011-05-23 |
| Est. Completion | 2018-10-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01266460
The ClinicalTrials.gov registry entry for NCT01266460 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01266460 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01266460 about?
NCT01266460 is a clinical study titled "Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer". This phase II trial studies the side effects and how well vaccine therapy works in treating patients with cervical cancer that does not go to remission despite treatment (persistent) or has come back (recurrent). Vaccines therapy may help the body build an effective immune response to kill tumor cel...
What is the current status of trial NCT01266460?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2011-05-23. Estimated completion is 2018-10-02.
What interventions are being tested in trial NCT01266460?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01266460?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.